We are live on ! Find out more
GILD icon

Gilead Sciences

1,326 hedge funds and large institutions have $139B invested in Gilead Sciences in 2014 Q3 according to their latest regulatory filings, with 126 funds opening new positions, 465 increasing their positions, 615 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

147% more first-time investments, than exits

New positions opened: 126 | Existing positions closed: 51

46% more funds holding in top 10

Funds holding in top 10: 164240 (+76)

20% more capital invested

Capital invested by funds: $116B → $139B (+$22.7B)

5% more funds holding

Funds holding: 1,2621,326 (+64)

24% less repeat investments, than reductions

Existing positions increased: 465 | Existing positions reduced: 615

36% less call options, than puts

Call options by funds: $2.53B | Put options by funds: $3.96B

Holders
1,326
Holders Change
+64
Holders Change %
+5.07%
% of All Funds
38.47%
Holding in Top 10
240
Holding in Top 10 Change
+76
Holding in Top 10 Change %
+46.34%
% of All Funds
6.96%
New
126
Increased
465
Reduced
615
Closed
51
Calls
$2.53B
Puts
$3.96B
Net Calls
-$1.43B
Net Calls Change
-$802M
Name Holding Trade Value Shares
Change
Change in
Stake
ITIM
901
Indiana Trust & Investment Management
Indiana
$1.37M -$10.3K -105 -0.8%
RW
902
Rand Wealth
Maryland
$1.34M -$34.3K -350 -3%
ATC
903
Argent Trust Company
Louisiana
$1.34M -$10.8K -110 -0.9%
SAG
904
Sterne Agee Group
Alabama
$1.34M +$1.23M +12,559 New
Acadian Asset Management
905
Acadian Asset Management
Massachusetts
$1.33M +$174K +1,780 +17%
DCLA
906
Douglas C. Lane & Associates
New York
$1.33M +$397K +4,055 +48%
SAMNY
907
Samsung Asset Management (New York)
New York
$1.33M -$3.19M -32,540 -72%
AIC
908
Atlantic Investment Company
Georgia
$1.32M -$1.27M -12,985 Closed
HB
909
Homrich & Berg
Georgia
$1.31M +$955K +9,748 +378%
SGAM
910
Steinberg Global Asset Management
Florida
$1.3M +$21.6K +221 +2%
BIM
911
Beach Investment Management
Pennsylvania
$1.3M
GD
912
Grandfield & Dodd
New York
$1.3M +$25.9K +264 +2%
PC
913
Passport Capital
California
$1.28M +$813K +8,299 +220%
FNBOH
914
First National Bank of Hutchinson
Kansas
$1.26M +$7.64K +78 +0.7%
MCM
915
Moore Capital Management
New York
$1.25M +$1.15M +11,734 New
CCA
916
Checchi Capital Advisers
California
$1.24M +$334K +3,409 +41%
BEC
917
Blue Edge Capital
Virginia
$1.23M -$39.4K -402 -3%
FIM
918
Freedom Investment Management
Connecticut
$1.21M +$51.6K +527 +5%
PMG
919
ProVise Management Group
Florida
$1.2M +$176K +1,800 +19%
PSI
920
Pinnacle Summer Investments
Virginia
$1.19M +$490K +5,000 +81%
SFA
921
Sequoia Financial Advisors
Ohio
$1.19M +$8.03K +82 +0.7%
MIC
922
MU Investments Company
Japan
$1.17M -$458K -4,680 -30%
LCM
923
Logan Capital Management
Pennsylvania
$1.17M -$196K -2,000 -15%
MCM
924
Manchester Capital Management
Vermont
$1.17M -$107K -1,097 -9%
AWA
925
AmeriServ Wealth Advisors
Pennsylvania
$1.17M +$34.6K +353 +3%

GILD Hedge Fund Activity: Q3 2014 in Review

1,326 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2014, worth a combined $139B — up 20% from $116B a quarter earlier.

Buyers outnumbered sellers: 126 funds opened new GILD positions and 51 closed out — a net gain of 75 holders — while 465 added to existing stakes and 615 trimmed.

The largest buyer was BNP Paribas Financial Markets, adding an estimated $226M. The largest seller was Capital Research Global Investors, cutting an estimated $1.52B.

  • 1,326 institutional investors held Gilead Sciences (GILD) as of Q3 2014, up from 1,262 in Q2 2014.
  • Funds reported $139B of Gilead Sciences stock for Q3 2014, up 20% quarter-over-quarter.
  • 126 funds opened new Gilead Sciences positions in Q3 2014 and 51 closed out, a net change of +75 holders.
  • The largest Gilead Sciences buyer in Q3 2014 was BNP Paribas Financial Markets, an estimated $226M added.
  • The largest Gilead Sciences seller in Q3 2014 was Capital Research Global Investors, an estimated $1.52B sold.

Based on aggregated 13F filings for Q3 2014.